Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pazopanib in high-risk soft tissue sarcoma (FDG-PET window-of-opportunity study)
2011-003745-18Phase 2Terminated
- Sponsor
- Heidelberg University
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in soft tissue sarcoma (STS), sponsored by Heidelberg University. Primary endpoint: Metabolic response rate (MRR). Started Apr 2012; status: terminated.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2011-003745-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003745-18.